Achondroplasia is a genetic disorder that causes short stature called dwarfism and a large head, also known as macrocephaly. It is a disorder in which bone and cartilage do not grow normally. It is the most common cause of dwarfism.
This condition leads to people reaching a full-grown height of around 4-4½ feet. The greatest shortening occurs in the bone between the shoulder and the elbow and the bone between the hip and the knee. There may also be underdevelopment of the face.
Achondroplasia is a genetic disorder. It is caused by mutations in the FGFR3 gene. This gene prevents the growth of cartilage at the growth plate. FGFR3 encodes a protein called Fibroblast Growth Factor Receptor 3. This protein is the site of action of a major growth factor responsible for lengthening bones. When this growth factor cannot act properly due to the absence of its receptor, the growth of bones, at the growth plate's cartilage, is slowed. This leads to shorter bones, abnormally shaped bones, and shorter stature.
The gene for achondroplasia can be passed from one generation to the next. If a parent has the disorder, there is a 50% chance of passing the gene for achondroplasia to children. In most cases of achondroplasia, it more commonly is the result of a sudden genetic defect that occurs in the developing embryo.
Factors that may increase the chance of achondroplasia include:
Symptoms of achondroplasia include:
Other common symptoms include:
The doctor will ask about your symptoms and medical history. A physical exam will be done. The strength of your extremities and your bladder control will be evaluated. Weakness and loss of bladder control are both signs of spinal stenosis, which is a narrowing of the spinal canal. It is important to follow the doctor's advice to make sure that
does not develop without being recognized. This generally occurs between the ages of 20-40 years.
Your bodily fluids may be tested. This can be done with blood tests.
Images may be taken of your bodily structures. This can be done with:
At this time, there is no cure for achondroplasia.
Scientists are exploring ways to create alternate growth factors which can bypass the missing receptor and lead to normal bone growth. They may offer the possibility of enhanced stature to future families who have children with achondroplasia.
Treatment with human growth hormone has been used for over a decade. It effectively increases bone growth rate, at least in the first year of life. There have been few studies looking at whether children treated with growth hormone achieve greater adult height.
Surgery is sometimes needed to correct specific skeletal deformities.
Osteotomy has primarily been used to correct deformities. In recent years, bone lengthening procedures have been used for many short-statured children, including those with achondroplasia. The procedures are lengthy, traumatic, and demanding for both children and their families. Complications, sometimes serious, are common. One center has reported an average leg length gain of about 7 inches and an average increase in arm length of about 4 inches for achondroplastic individuals who undergo surgery. The combination of growth hormone therapy followed by lengthening surgery may provide benefit in achieving near-normal stature and proportions.
There are no steps to prevent a genetic disorder. Genetic counseling can be used to discuss the chances that your child will have achondroplasia. You may consider this counseling if you are planning on having a child and have a family history of genetic conditions.
Healthy Children—American Academy of Pediatrics
Little People of America
Caring for Kids—Canadian Paediatrics Society
Little People of Ontario
Achondroplasia. EBSCO Plus DynaMed website. Available at:
http://www.dynamed.com/topics/dmp~AN~T114336/Acute-intestinal-pseudo-obstruction. Updated January 10, 2011. Accessed March 8, 2016.
Aldegheri R, Dall'Oca C. Limb lengthening in short stature patients.
J Pediatr Orthop B. 2001;10(3):238-247.
Aviezer D, Golembo M, Yayon A. Fibroblast growth factor receptor-3 as a therapeutic target for achondroplasia—genetic short limbed dwarfism.
Curr Drug Targets. 2003;4(5):353-65.
Last reviewed March 2016 by James Cornell, MD
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.